Form 4: Karyopharm Therapeutics EVP Reshma Rangwala Reports Stock Sale to Cover Tax Obligations

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, reports selling 419 shares of common stock to cover withholding tax liabilities.

Summary

• Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics Inc., filed a Form 4 on April 24, 2025, reporting a transaction involving the company's common stock.
• On April 23, 2025, Rangwala sold 419 shares of common stock at a price of $6.17 per share.
• The sale was executed under a pre-arranged automatic sale plan adopted on April 4, 2022, to cover withholding tax obligations related to the vesting of restricted stock units.
• Following the transaction, Rangwala directly owns 28,853 shares of Karyopharm Therapeutics Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This particular filing relates to the sale of shares to cover tax obligations, which is a common practice.

Key Dates

Keywords

Form 4, Karyopharm Therapeutics, Reshma Rangwala, Stock Sale, Executive Compensation, Insider Trading, Automatic Sale Plan, Withholding Tax